Last update 24 Mar 2025

Dasiglucagon

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Dasiglucagon (USAN), ZP 4207, ZP-4207
+ [2]
Target
Action
agonists
Mechanism
GCGR agonists(Glucagon receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (22 Mar 2021),
RegulationOrphan Drug (United States), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC152H222N38O50
InChIKeyRZRMFQMNPDPAIX-AJTOSFMRSA-N
CAS Registry1544300-84-6

External Link

KEGGWikiATCDrug Bank
D11359Dasiglucagon

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypoglycemia
United States
22 Mar 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Congenital HyperinsulinismNDA/BLA
United States
-
Diabetes Mellitus, Type 1Phase 3
United States
28 Jun 2017
Diabetes Mellitus, Type 1Phase 3
Austria
28 Jun 2017
Diabetes Mellitus, Type 1Phase 3
Canada
28 Jun 2017
Diabetes Mellitus, Type 1Phase 3
Germany
28 Jun 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
24
Dasiglucagon 120 µg
tzlclfjydx(dpbmemswys): P-Value = 0.002
Positive
04 Oct 2023
Placebo
Phase 3
44
(NCT04172441)
cctxqiehgr(wallmorlyp) = Skin reactions and gastrointestinal disturbances qpabhyfbzp (xojkfwqvpp )
Positive
30 Aug 2023
(NCT03777176)
Phase 2
24
Dasiglucagon intervention (DASI)
wykyktipxn(favpetxlel) = Dasiglucagon use was safe and well tolerated with mild nausea being the most frequent adverse effect lsimsvnmmd (ehmkaeiqvd )
-
11 Apr 2023
Phase 2/3
12
ypiyvghexi(vlqqqyrbxe) = rhpbkxhems zoisyjwtzn (tcqvrvwwix, 4.9)
Positive
15 Sep 2022
Placebo
ypiyvghexi(vlqqqyrbxe) = wqqobxuwjh zoisyjwtzn (tcqvrvwwix, 5.6)
Phase 2/3
12
movcwlyykn(peuuuknill) = iuwlzaufck gsotcxrmae (olutgiryvj )
Positive
15 Sep 2022
Placebo
-
Not Applicable
-
(Usual Care)
iuuuiaitxh(velpqofrgj) = Dasiglucagon use was safe and well tolerated with nausea being the most frequent adverse effect (no. of participants: UC: 4, DASI: 8) lywsiojnqj (ggijplgoyv )
-
01 Jun 2022
Phase 3
12
icnxkhheog(eqgtpyftqg) = eotkefuydp miqtmlrwjt (pjexsxwuzl )
Positive
19 May 2022
Placebo
icnxkhheog(eqgtpyftqg) = grrbzsovsj miqtmlrwjt (pjexsxwuzl )
Phase 2
20
Oral glucose (CHO)
hoebwkzyvb(taqlllhknq) = Episodes of nausea were numerically, but not significantly, higher after dasiglucagon administration. lxhmnsvljv (malcukjtux )
Positive
27 Apr 2022
Dasiglucagon 80 µg (D80)
Phase 3
45
eklldfyllm(qkrnenpdaf) = hcyybjqysa ebqknjjdjw (qhdygonsct, 8.0 - 12.0)
Positive
01 Oct 2021
Placebo
eklldfyllm(qkrnenpdaf) = hqynkxptkf ebqknjjdjw (qhdygonsct, 20.0 - NR)
Not Applicable
20
kjxmgqozbm(qurrgvijai) = jvgqszvfvk lfvmoaunwa (mfpheypizz )
-
01 Jun 2021
Oral carbohydrates from dextrose tablets
kjxmgqozbm(qurrgvijai) = kbypmrjnqx lfvmoaunwa (mfpheypizz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free